Potential of the conditionally replicative adenovirus Ad5-Δ24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy

Martine L M Lamfers, Jacques Grill, Clemens M F Dirven, Victor W. Van Beusechem, Birgit Geoerger, Jaap Van den Berg, Ramon Alemany, Juan Fueyo, David T. Curiel, Gilles Vassal, Herbert M. Pinedo, W. Peter Vandertop, Winald R. Gerritsen

Research output: Contribution to journalArticle

Abstract

The use of replication-competent adenoviruses (Ads) for cancer therapy is receiving widespread attention, especially for the treatment of tumors refractory to current treatments such as glioblastoma. ADΔ24, which carries a 24-bp deletion in E1A and replicates in cells with a retinoblastoma-defective pathway, produced a strong antitumor effect in glioma. To improve infection efficiency of primary glioma cells, which express low levels of coxsackie adenovirus receptor (CAR), the tropism of ADΔ24 was expanded toward αv integrins by insertion of an Arg-Gly-Asp (RGD) motif into the fiber knob (Ad5-Δ24RGD). We show that Ad5-Δ24RGD had a stronger oncolytic effect than the non-RGD-expressing variant on a broad panel of primary glioma cells, in particular on those with low CAR expression. The effects of Ad5-Δ24RGD were also assessed on a panel of primary organotypic glioma spheroids. In all cases, Ad5-Δ24RGD strongly decreased the viability of these small tumor nodules in vitro. In s.c. glioblastoma xenografts expressing low levels of CAR, five intratumoral injections of 1 × 107 plaque-forming units Ad5-Δ24RGD resulted in complete tumor regression in 9 of 10 mice and long-term survival in all treated mice. Preclinical evaluations and clinical trials of replication-competent Ad have shown more promising results when combined with conventional therapeutics. Therefore, we assessed the effects of Ad5-Δ24RGD in combination with radiotherapy. Low-dose irradiation before Ad5-Δ24RGD infection decreased viability of glioma cells more effectively than Ad5-Δ24RGD alone with effects ranging from additive to supra-additive. In addition, combination treatment with Ad5-Δ24RGD and irradiation was studied in glioma xenografts. Five injections of 1 × 106 plaque-forming units Ad5-Δ24RGD induced significant tumor growth delay of >119 days compared with untreated controls and led to long-term survival in 6 of 9 mice. When viral treatment was combined with irradiation, tumor regression occurred in all mice resulting in long-term survival without evidence of tumor regrowth in 10 of 10 cases. This study thus provides evidence that Ad5-Δ24RGD has strong antitumor activity in malignant glioma, which can be additionally enhanced by irradiation such that the same therapeutic effect is achieved when a 10-fold lower viral dose is applied. These results support further development of Ad5-Δ24RGD in combination with radiation therapy for treatment of these highly malignant tumors.

Original languageEnglish (US)
Pages (from-to)5736-5742
Number of pages7
JournalCancer Research
Volume62
Issue number20
StatePublished - Oct 15 2002
Externally publishedYes

Fingerprint

Adenoviridae
Glioma
Radiotherapy
Coxsackie and Adenovirus Receptor-Like Membrane Protein
Neoplasms
Therapeutics
Glioblastoma
Heterografts
Injections
Tropism
Retinoblastoma
Therapeutic Uses
Infection
Integrins
Cell Survival
Clinical Trials
Growth

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Lamfers, M. L. M., Grill, J., Dirven, C. M. F., Van Beusechem, V. W., Geoerger, B., Van den Berg, J., ... Gerritsen, W. R. (2002). Potential of the conditionally replicative adenovirus Ad5-Δ24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Research, 62(20), 5736-5742.

Potential of the conditionally replicative adenovirus Ad5-Δ24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. / Lamfers, Martine L M; Grill, Jacques; Dirven, Clemens M F; Van Beusechem, Victor W.; Geoerger, Birgit; Van den Berg, Jaap; Alemany, Ramon; Fueyo, Juan; Curiel, David T.; Vassal, Gilles; Pinedo, Herbert M.; Vandertop, W. Peter; Gerritsen, Winald R.

In: Cancer Research, Vol. 62, No. 20, 15.10.2002, p. 5736-5742.

Research output: Contribution to journalArticle

Lamfers, MLM, Grill, J, Dirven, CMF, Van Beusechem, VW, Geoerger, B, Van den Berg, J, Alemany, R, Fueyo, J, Curiel, DT, Vassal, G, Pinedo, HM, Vandertop, WP & Gerritsen, WR 2002, 'Potential of the conditionally replicative adenovirus Ad5-Δ24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy', Cancer Research, vol. 62, no. 20, pp. 5736-5742.
Lamfers MLM, Grill J, Dirven CMF, Van Beusechem VW, Geoerger B, Van den Berg J et al. Potential of the conditionally replicative adenovirus Ad5-Δ24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Research. 2002 Oct 15;62(20):5736-5742.
Lamfers, Martine L M ; Grill, Jacques ; Dirven, Clemens M F ; Van Beusechem, Victor W. ; Geoerger, Birgit ; Van den Berg, Jaap ; Alemany, Ramon ; Fueyo, Juan ; Curiel, David T. ; Vassal, Gilles ; Pinedo, Herbert M. ; Vandertop, W. Peter ; Gerritsen, Winald R. / Potential of the conditionally replicative adenovirus Ad5-Δ24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. In: Cancer Research. 2002 ; Vol. 62, No. 20. pp. 5736-5742.
@article{85496440b43f4ea4bb6a72e74154fdc1,
title = "Potential of the conditionally replicative adenovirus Ad5-Δ24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy",
abstract = "The use of replication-competent adenoviruses (Ads) for cancer therapy is receiving widespread attention, especially for the treatment of tumors refractory to current treatments such as glioblastoma. ADΔ24, which carries a 24-bp deletion in E1A and replicates in cells with a retinoblastoma-defective pathway, produced a strong antitumor effect in glioma. To improve infection efficiency of primary glioma cells, which express low levels of coxsackie adenovirus receptor (CAR), the tropism of ADΔ24 was expanded toward αv integrins by insertion of an Arg-Gly-Asp (RGD) motif into the fiber knob (Ad5-Δ24RGD). We show that Ad5-Δ24RGD had a stronger oncolytic effect than the non-RGD-expressing variant on a broad panel of primary glioma cells, in particular on those with low CAR expression. The effects of Ad5-Δ24RGD were also assessed on a panel of primary organotypic glioma spheroids. In all cases, Ad5-Δ24RGD strongly decreased the viability of these small tumor nodules in vitro. In s.c. glioblastoma xenografts expressing low levels of CAR, five intratumoral injections of 1 × 107 plaque-forming units Ad5-Δ24RGD resulted in complete tumor regression in 9 of 10 mice and long-term survival in all treated mice. Preclinical evaluations and clinical trials of replication-competent Ad have shown more promising results when combined with conventional therapeutics. Therefore, we assessed the effects of Ad5-Δ24RGD in combination with radiotherapy. Low-dose irradiation before Ad5-Δ24RGD infection decreased viability of glioma cells more effectively than Ad5-Δ24RGD alone with effects ranging from additive to supra-additive. In addition, combination treatment with Ad5-Δ24RGD and irradiation was studied in glioma xenografts. Five injections of 1 × 106 plaque-forming units Ad5-Δ24RGD induced significant tumor growth delay of >119 days compared with untreated controls and led to long-term survival in 6 of 9 mice. When viral treatment was combined with irradiation, tumor regression occurred in all mice resulting in long-term survival without evidence of tumor regrowth in 10 of 10 cases. This study thus provides evidence that Ad5-Δ24RGD has strong antitumor activity in malignant glioma, which can be additionally enhanced by irradiation such that the same therapeutic effect is achieved when a 10-fold lower viral dose is applied. These results support further development of Ad5-Δ24RGD in combination with radiation therapy for treatment of these highly malignant tumors.",
author = "Lamfers, {Martine L M} and Jacques Grill and Dirven, {Clemens M F} and {Van Beusechem}, {Victor W.} and Birgit Geoerger and {Van den Berg}, Jaap and Ramon Alemany and Juan Fueyo and Curiel, {David T.} and Gilles Vassal and Pinedo, {Herbert M.} and Vandertop, {W. Peter} and Gerritsen, {Winald R.}",
year = "2002",
month = "10",
day = "15",
language = "English (US)",
volume = "62",
pages = "5736--5742",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - Potential of the conditionally replicative adenovirus Ad5-Δ24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy

AU - Lamfers, Martine L M

AU - Grill, Jacques

AU - Dirven, Clemens M F

AU - Van Beusechem, Victor W.

AU - Geoerger, Birgit

AU - Van den Berg, Jaap

AU - Alemany, Ramon

AU - Fueyo, Juan

AU - Curiel, David T.

AU - Vassal, Gilles

AU - Pinedo, Herbert M.

AU - Vandertop, W. Peter

AU - Gerritsen, Winald R.

PY - 2002/10/15

Y1 - 2002/10/15

N2 - The use of replication-competent adenoviruses (Ads) for cancer therapy is receiving widespread attention, especially for the treatment of tumors refractory to current treatments such as glioblastoma. ADΔ24, which carries a 24-bp deletion in E1A and replicates in cells with a retinoblastoma-defective pathway, produced a strong antitumor effect in glioma. To improve infection efficiency of primary glioma cells, which express low levels of coxsackie adenovirus receptor (CAR), the tropism of ADΔ24 was expanded toward αv integrins by insertion of an Arg-Gly-Asp (RGD) motif into the fiber knob (Ad5-Δ24RGD). We show that Ad5-Δ24RGD had a stronger oncolytic effect than the non-RGD-expressing variant on a broad panel of primary glioma cells, in particular on those with low CAR expression. The effects of Ad5-Δ24RGD were also assessed on a panel of primary organotypic glioma spheroids. In all cases, Ad5-Δ24RGD strongly decreased the viability of these small tumor nodules in vitro. In s.c. glioblastoma xenografts expressing low levels of CAR, five intratumoral injections of 1 × 107 plaque-forming units Ad5-Δ24RGD resulted in complete tumor regression in 9 of 10 mice and long-term survival in all treated mice. Preclinical evaluations and clinical trials of replication-competent Ad have shown more promising results when combined with conventional therapeutics. Therefore, we assessed the effects of Ad5-Δ24RGD in combination with radiotherapy. Low-dose irradiation before Ad5-Δ24RGD infection decreased viability of glioma cells more effectively than Ad5-Δ24RGD alone with effects ranging from additive to supra-additive. In addition, combination treatment with Ad5-Δ24RGD and irradiation was studied in glioma xenografts. Five injections of 1 × 106 plaque-forming units Ad5-Δ24RGD induced significant tumor growth delay of >119 days compared with untreated controls and led to long-term survival in 6 of 9 mice. When viral treatment was combined with irradiation, tumor regression occurred in all mice resulting in long-term survival without evidence of tumor regrowth in 10 of 10 cases. This study thus provides evidence that Ad5-Δ24RGD has strong antitumor activity in malignant glioma, which can be additionally enhanced by irradiation such that the same therapeutic effect is achieved when a 10-fold lower viral dose is applied. These results support further development of Ad5-Δ24RGD in combination with radiation therapy for treatment of these highly malignant tumors.

AB - The use of replication-competent adenoviruses (Ads) for cancer therapy is receiving widespread attention, especially for the treatment of tumors refractory to current treatments such as glioblastoma. ADΔ24, which carries a 24-bp deletion in E1A and replicates in cells with a retinoblastoma-defective pathway, produced a strong antitumor effect in glioma. To improve infection efficiency of primary glioma cells, which express low levels of coxsackie adenovirus receptor (CAR), the tropism of ADΔ24 was expanded toward αv integrins by insertion of an Arg-Gly-Asp (RGD) motif into the fiber knob (Ad5-Δ24RGD). We show that Ad5-Δ24RGD had a stronger oncolytic effect than the non-RGD-expressing variant on a broad panel of primary glioma cells, in particular on those with low CAR expression. The effects of Ad5-Δ24RGD were also assessed on a panel of primary organotypic glioma spheroids. In all cases, Ad5-Δ24RGD strongly decreased the viability of these small tumor nodules in vitro. In s.c. glioblastoma xenografts expressing low levels of CAR, five intratumoral injections of 1 × 107 plaque-forming units Ad5-Δ24RGD resulted in complete tumor regression in 9 of 10 mice and long-term survival in all treated mice. Preclinical evaluations and clinical trials of replication-competent Ad have shown more promising results when combined with conventional therapeutics. Therefore, we assessed the effects of Ad5-Δ24RGD in combination with radiotherapy. Low-dose irradiation before Ad5-Δ24RGD infection decreased viability of glioma cells more effectively than Ad5-Δ24RGD alone with effects ranging from additive to supra-additive. In addition, combination treatment with Ad5-Δ24RGD and irradiation was studied in glioma xenografts. Five injections of 1 × 106 plaque-forming units Ad5-Δ24RGD induced significant tumor growth delay of >119 days compared with untreated controls and led to long-term survival in 6 of 9 mice. When viral treatment was combined with irradiation, tumor regression occurred in all mice resulting in long-term survival without evidence of tumor regrowth in 10 of 10 cases. This study thus provides evidence that Ad5-Δ24RGD has strong antitumor activity in malignant glioma, which can be additionally enhanced by irradiation such that the same therapeutic effect is achieved when a 10-fold lower viral dose is applied. These results support further development of Ad5-Δ24RGD in combination with radiation therapy for treatment of these highly malignant tumors.

UR - http://www.scopus.com/inward/record.url?scp=0037109013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037109013&partnerID=8YFLogxK

M3 - Article

C2 - 12384532

AN - SCOPUS:0037109013

VL - 62

SP - 5736

EP - 5742

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 20

ER -